"动脉样硬化中的抗炎疗法 - - 我们正走向何方?"
Natdanai Punnanithinont1, Soumya Kambalapalli2, Beshoy Iskander2
1The Lundquist Institute, UCLA Medical Center Harbor, 1124 W Carson St, CA 90502, Torrance, US. n.punnanithinont@lundquist.org.
Current atherosclerosis reports
|December 19, 2024
概括
低剂量胆固醇可以有效地减少动脉样硬化患者的心血管事件. 针对炎症的新型疗法,如IL-6抑制剂,显示出希望,特别是在慢性脏病患者中,尽管黄素仍然具有成本效益.
科学领域:
- 心血管医学 心血管医学
- 炎症生物学 炎症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症是动脉样硬化的关键因素,与脂质积累一起.
- 炎症生物标志物升高在一些患者中仍然存在,尽管最佳的降脂疗法.
- 抗炎症疗法旨在减轻残留心血管风险.
研究的目的:
- 审查涉及动脉样硬化的主要炎症途径.
- 总结最近关于心血管疾病抗炎疗法的临床试验.
- 评估新型抗炎药物的潜力.
主要方法:
- 对临床试验数据的分析,包括对菌素的COLCOT和LoDoCo2的分析.
- 对抗IL-6 (IL-6) 抑制的研究的审查,例如RESCUE试验.
- 检查正在进行的3期试验,如ZEUS用于晚期慢性病患者.
主要成果:
- 低剂量胆固醇可显著减少近期心脏病发作和慢性冠状动脉疾病患者的心血管事件.
- 胆固醇是FDA批准用于动脉样硬化心血管疾病 (ASCVD),但对慢性病 (CKD) 患者有局限性.
- 齐尔提维基马布 (IL-6抑制剂) 降低了高级CKD患者的高灵敏度C反应蛋白 (hs-CRP),ZEUS试验正在进行中.
结论:
- 科尔奇辛是一种具有成本效益的抗炎药物,可用于治疗心血管疾病.
- 抑制IL-6对患有动脉样硬化心血管疾病和炎症的CKD患者来说是有前途的.
- 进一步的研究对于新型抗炎疗法及其临床实施至关重要.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:38Inflammation
52.5K
Overview
52.5K